Summit Therapeutics Inc (SMMT)

Summit Therapeutics' stock price has fluctuated over the past six months, decreasing by 11.98% between March 31, 2025, and March 30, 2026, and 19.51% over the last 12 months, with a 52-week trading range of $13.83 to $36.91. Key events include the company reporting an EPS of -$0.14 for Q4 2025, missing analysts' consensus estimates. Analyst ratings have varied, with Jefferies Financial Group downgrading the stock to "hold" and Truist Financial upgrading it to a "strong-buy". Summit filed an FDA application for ivonescimab, with a decision expected by November 14, 2026, and presented ivonescimab data at ELCC 2026 and investor conferences.

As a clinical-stage biopharmaceutical company, Summit Therapeutics, Inc.'s business model is primarily focused on the discovery, development, and clinical trials of novel therapeutics rather than the commercial sale of approved products. Therefore, traditional demand seasonality is not a significant factor for the company's products and services at its current stage.

Summit Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for unmet medical needs, particularly in oncology and infectious diseases. The company's primary focus is its oncology pipeline, led by ivonescimab, a bispecific antibody targeting PD-1 and VEGF pathways, being developed for various solid tumor cancers, especially non-small cell lung cancer (NSCLC).

Summit Therapeutics is headquartered in Miami, Florida, with additional offices in Palo Alto, California; Princeton, New Jersey; Oxford, United Kingdom; and Dublin, Ireland. Its operational footprint is primarily in the United States, with international influence through its collaboration with Akeso, Inc. in China. Summit has strategic exposure to North America, Europe, and parts of Asia-Pacific, focusing on the United States, China, and other major pharmaceutical markets, identifying the United States and the United Kingdom as its two geographical segments.

Summit Therapeutics achieved the "Great Place to Work® Certification™," indicating a positive work environment. Analyst sentiment is generally positive, with an average rating of "Moderate Buy" from 17 research firms and an average 1-year target price of $29.83. No specific negative events directly affecting Summit Therapeutics' brand reputation were widely reported in the past year.

Summit Therapeutics, Inc. has a diverse ownership structure, with 215 institutional owners holding 117,365,196 shares, accounting for approximately 15.3% of the company. Major institutional shareholders include Baker Bros. Advisors Lp, Fmr Llc, and Vanguard Group Inc. Individual insiders hold a substantial portion of the company, owning 78.6% of the shares, with Mahkam Zanganeh being the largest individual shareholder, owning 82.61% of the company's shares.